Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Effective nose-to-brain delivery of exendin-4 via coadministration with cell-penetrating peptides for improving progressive cognitive dysfunction
doi: 10.1007/s00125-012-2592-3 115 LenerM
fast Download PDF Now- 20262029 pipeline snapshot: Novo Nordisk CagriSema (GLP-1 + amylin) Filing 2026 Lilly Orforglipron (oral GLP-1) + Retatrutide (triple agonist) Launch window 20262027 Amgen Maritide (GLP-1 + GIP) 20272028 target BI / Zealand Survodutide (GLP-1 + glucagon) 2027 Altimmune Pemvidutide (GLP-1 + glucagon) 2027 Roche CT-388 / Petrelintide possible 2029 And one notable miss: Pfizer Danuglipron discontinued Clear trend: Single GLP-1 dual triple agonists Competition is shifting from: Who has a GLP-1? to Who has the most effective combination biology? Execution risk is still real but the bar for efficacy is moving quickly
Am J Chinese Med
Its simple, the math is clean, and its the most common practice in research settings
US$ 26.35
US$ 21.91
US$ 24.14
US$ 23.51
US$ 20.63
US$ 28.16
